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Secretory A2 phospholipases (sPLA2) hydrolyze surfactant phospholipids cause surfactant dysfunction and are elevated in lung inflammation.
Phospholipase-mediated surfactant hydrolysis may disrupt surfactant function by generation of lysophospholipids and free fatty acids and/or
depletion of native phospholipids. In this study, we quantitatively assessed multiple mechanisms of sPLA2-mediated surfactant dysfunction using
non-enzymatic models including supplementation of surfactants with exogenous lysophospholipids and free fatty acids. Our data demonstrated
lysophospholipids at levels 10 mol% of total phospholipid (i.e., 10% hydrolysis) led to a significant increase in minimum surface tension and
increased the time to achieve a normal minimum surface tension. Lysophospholipid inhibition of surfactant function was independent of the
lysophospholipid head group or total phospholipid concentration. Free fatty acids (palmitic acid, oleic acid) alone had little effect on minimum
surface tension, but did increase the maximum surface tension and the time to achieve normal minimum surface tension. The combined effect of
equimolar free fatty acids and lysophospholipids was not different from the effect of lysophospholipids alone for any measurement of surfactant
function. Surfactant proteins did not change the percent lysophospholipids required to increase minimum surface tension. As a mechanism that
causes surfactant dysfunction, depletion of native phospholipids required much greater change (equivalent to >80% hydrolysis) than generation of
lysophospholipids. In summary, generation of lysophospholipids is the principal mechanism of phospholipase-mediated surfactant injury in our
non-enzymatic models. These models and findings will assist in understanding more complex in vitro and in vivo studies of phospholipase-
mediated surfactant injury.
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Pulmonary surfactant facilitates the work of breathing by
reducing surface tension in alveoli and small conducting
airways [1–4]. This surface activity is due to the combined
physical properties and complex interactions of phospholipids
(¨80%), neutral lipids (¨10%) and proteins (¨10%) [5]. The0005-2736/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2005.10.014
Abbreviations: BAL, bronchoalveolar lavage; sPLA2, secretory phospho-
lipase A2; ARDS, acute respiratory distress syndrome; PL, phospholipid; PC,
phosphatidylcholine; DPPC, dipalmitoylphosphatidylcholine; PG, phosphati-
dylglycerol; LPC, lysophosphatidylcholine; LPG, lysophosphatidylglycerol
* Corresponding author. Tel.: +1 336 716 4649; fax: +1 336 716 7277.
E-mail address: dhite@wfubmc.edu (R.D. Hite).phospholipid and protein components of surfactant are depleted
in lung diseases characterized by acute inflammation including
the acute respiratory distress syndrome (ARDS) [6–8], burn
injury [9], and asthma [10–13].
Approximately 80% of the phospholipid component in
surfactant is phosphatidylcholine (PC), and 50% of the PC
component is dipalmitoyl-PC, which is essential for maximal
surface tension lowering activity [5,14]. The second most
abundant surfactant phospholipid (¨10%) is the anionic
phosphatidylglycerol (PG) which plays an important role in
phospholipid–protein interactions [15,16]. The fatty acid
content of PG and the other surfactant-associated phospholi-
pids are similar to that reported for PC.ta 1720 (2005) 14 – 21
http://www
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surfactant in vitro and disrupt surfactant’s surface tension lowe-
ring activity [17,18]. Secretory phospholipases hydrolyze the
sn-2 fatty acid from a phospholipid glycerol backbone, produ-
cing a free fatty acid and a lysophospholipid, generally without
preference for specific sn-2 fatty acids [19–21]. For example,
sPLA2-mediated hydrolysis of PC produces lysophosphatidyl-
choline (LPC) and free fatty acids including palmitic acid, oleic
acid and linoleic acid [22,23]. The lack of fatty acid preference
by sPLA2’s is distinct from cytosolic PLA2’s (cPLA2) which
preferentially target intracellular arachidonic acid leading to
subsequent production of leukotrienes and prostaglandins [24].
There are ten known human sPLA2 genes [20,25–27].
Several sPLA2 have been identified in lung tissue and in
leukocytes that infiltrate the inflamed lung [28–32]. Elevated
sPLA2 activity has been demonstrated in bronchoalveolar lavage
(BAL) fluid in animal models of lung inflammation [33,34] and
human studies of ARDS and asthma [12,13,33,35–37].
Increasing concentrations of group IB sPLA2 caused parallel
increases in both hydrolysis of surfactant PL and increased
minimal surface tension. We have recently observed hydrolysis
of surfactant PL and surfactant dysfunction by other human
sPLA2s, including groups IIA, IID, V and X [18,31]. Despite
the consistency of each enzyme being able to cause surfactant
dysfunction, the efficiency of hydrolysis against the principal
phospholipids (PC, PG and phosphatidylethanolamine) varies
substantially with each enzyme. This apparent discrepancy
suggests that multiple mechanisms contribute to the ability of
sPLA2’s to lead to surfactant dysfunction.
The three most obvious mechanisms of sPLA2-mediated sur-
factant dysfunction are: the release of lysophospholipids, which
can disrupt the packing of the phospholipid film at the air–liquid
interface as reported by Holm et al. [38], release of free fatty
acids, which can also disrupt packing of the phospholipid film,
or the depletion of phospholipid leading to an inability to
maintain the phospholipid film. In this report, we quantitatively
assess the impact of each of these mechanisms using in vitro
non-enzymatic models. Our results demonstrate that lysopho-
spholipids have a greater effect on disrupting surfactant surface
tension than free fatty acids or total phospholipid depletion.
2. Materials and methods
2.1. Materials
All lysophospholipids and fatty acids were obtained from Avanti Lipids
(Alabaster, AL) and include: 1-palmitoyl-glycerolphosphocholine, 1-palmitoy-
glycerolphosphoglycerol, palmitic acid, oleic acid and arachidonic acid.
SurvantaR is a commercially available extracted surfactant (Ross Laboratories,
St. Louis, MO). Porcine surfactant was obtained from whole lung lavage of
juvenile pigs post euthanasia (graciously provided by Dr. Jakob Vinten-
Johanssen). To maintain high levels of hydrophobic and hydrophilic surfactant
proteins, the porcine surfactant was washed repetitively with saline as described
[17], but not organically extracted.
2.2. Surfactant function
A pulsating bubble surfactometer (Electronetics, Amherst, NY) was used to
quantitate several measurements of surfactant surface tension (c) loweringactivity [39]. Unless otherwise stated, all measurements were made at a final
concentration of 1.2 Amol phospholipid/ml (equal to 1 mg/ml), in buffered
saline containing 5 mM CaCl2 [17]. Pulsations were continued for a
maximum of 10 min or until c1.0 mN/m for at least 3 min. The minimum
surface tension (cmin) represents the minimum surface tension of at least 3
consecutive min achieved during each 10 min run [17]. The maximum
surface tension (cmax) represents the initial surface tension value obtained
prior to the onset of pulsations. Time to achieve a normal cmin represents the
time to reach and maintain a value of c3 mN/m, defined by the upper
confidence limit (99.9% ) for all cmin measurements of native Survanta during
these experiments.
2.3. Non-enzymatic models of hydrolysis
To model the impact of lysophospholipid and fatty acid generation on
surfactant function, samples of surfactant were mixed daily by initially drying
an aliquot of lysophospholipid or free fatty acid under N2 in a glass mixing tube
to which surfactant was added for a final total phospholipid concentration of
1.2 Amol/ml. Concentrations of supplemented lysophospholipids and fatty
acids are reported as % of total phospholipids on a mole:mole basis, which
equates to the % hydrolysis. The total concentration of phospholipids including
native surfactant phospholipids (SurvantaR or porcine surfactant), exogenous
lysophospholipids, and exogenous free fatty acids was maintained at 1.2 Amol/
ml for all experiments. This approach was utilized in order to accurately mimic
and compare the effects of the individual hydrolysis products. Mixing of the
supplemented lysophospholipid and fatty acid into the surfactant was achieved
using repetitive vortexing at 37 -C for a minimum of 30 min [17]. Phospholipid
concentrations were determined prior to mixing based on the measurement of
lipid phosphorus [40].
To model the impact of total phospholipid depletion in isolation from the
effects of hydrolysis products, we diluted surfactant preparations with Tris-
buffered saline (5 mM, pH 7.4) containing 5 mM CaCl2 to achieve final
phospholipid concentrations of 0.12–2.4 Amol/ml. Reduction of phospholipid
concentration equates to the % loss of total phospholipids from 1.2 Amol/ml
standard used in the surfactometer.
To assess the impact of surfactant-associated proteins in our model, two
surfactant mixtures were used. SurvantaR contains only small amounts of the
hydrophobic surfactant proteins (SP-B, SP-C) and no hydrophilic surfactant
proteins (SP-A, SP-D). Juvenile porcine surfactant, which was not organically
extracted, contains all surfactant proteins. In separate studies, endogenous
concentrations of LPC and LPG have been measured in SurvantaR (1.0% and
0.4% mole/mole, respectively), and in porcine surfactant (<0.5% for both)
using HPLC and evaporative light scatter [13].
2.4. Statistics
All data are presented as the meanTS.E.M. of at least 3 experiments.
Significance was evaluated by unpaired t-test, assuming equal variance and
using one-tailed (cmin and time to achieve a normal cmin) and two-tailed t-tests
(cmax) where appropriate.
3. Results
3.1. Accumulation of lysophospholipids
Hydrolysis of surfactant by sPLA2 generates lysopho-
spholipids that may have detergent effects, altering the surface
lowering function of the surfactant film. To quantitatively
assess the effect of lysophospholipids on surfactant function,
LPC was substituted for SurvantaR at increasing concentra-
tions while maintaining a total phospholipid concentration of
1.2 Amol/ml. At LPC concentrations of 10 mol%, cmin
significantly increased in a dose dependent manner (P <0.01,
Fig. 1). Remarkably similar results were obtained when LPG
was supplemented into the surfactant instead of LPC which
Fig. 1. Effect of lysophospholipid on minimum surface tension. Surfactant
PL (SurvantaR) was replaced with either lysophosphatidylcholine or
lysophosphatidylglycerol on an equimolar basis. Final phospholipid concen-
tration (including exogenous lysophospholipids) in all experiments was 1.2
Amol/ml. Minimum surface tension (cmin) was measured in a pulsating
bubble surfactometer. Significantly increased surface tension was seen at
lysophospholipid levels >10 mol% LPC ( P <0.01) and 15 mol% LPG
( P0.02).
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(P0.02). These results suggest disruption of phospholipid
packing is mediated more by loss of the acyl chains at the sn-2
position than the head group structure.
3.2. Accumulation of free fatty acids
The other products generated by sPLA2-mediated hydrolysis
of phospholipids are free fatty acids (FFA). Palmitic acid is the
most abundant fatty acid in pulmonary surfactant. When
palmitic acid was added to SurvantaR, no significant increase
in cmin was seen even at the highest concentration (30 mol%),
which equates to 30% hydrolysis (Fig. 2). Oleic acid, aFig. 2. Effect of free fatty acid content on minimum surface tension.
Surfactant PL (SurvantaR) was replaced with a free fatty acid (FFA)
including palmitic acid (PA), oleic acid (OA) or arachidonic acid (AA) on
an equimolar basis. Final phospholipid concentration in the sample without
FFA was 1.2 Amol/ml, but decreased as increasing phospholipid was
substituted by fatty acid. Minimum surface tension (cmin) was measured in
a pulsating bubble surfactometer. PA did not significantly increase cmin, but
significantly increased cmin was seen with OA (>15 mol%, P <0.02) and AA
(>5 mol%, P <0.01).monounsaturated fatty acid also present in surfactant, did
significantly increase cmin at concentrations of >15 mol%
(P <0.02), but the magnitude of surfactant dysfunction was
less than seen with the lysophospholipids. The highly
unsaturated arachidonic acid significantly increased cmin at
concentrations 5 mol% (P <0.01). Although a potential role
for arachidonic acid liberation from fetal surfactant has been
described [41], in general, arachidonate levels in most
pulmonary surfactants are extremely low a and therefore
should not play a significant role in sPLA2-mediated surfactant
hydrolysis and dysfunction.
3.3. Combination of lysophospholipids and free fatty acids
Since sPLA2-mediated hydrolysis of a phospholipid simul-
taneously produces a lysophospholipid and a free fatty acid
(FFA) in equimolar amounts, we also simultaneously supple-
mented surfactant with LPC and a FFA (Fig. 3). Neither
palmitic acid nor oleic acid added in equimolar amounts with
LPC altered the threshold concentration of 10 mol% LPC
required to produce significantly increased cmin values. Only
palmitic acid added at 15 mol% increased surface tension to a
greater magnitude than LPC alone, although the mechanism of
this is unknown. These results suggest that FFA’s provide little
synergistic effect to the disruption of minimum surface tension
caused by lysophospholipids.
3.4. Depletion of total phospholipid
Secretory PLA2s will not only produce lysophospholipid
and free fatty acids by hydrolyzing PL, they will also deplete
the concentration of intact PL in a surfactant film. The effect of
PL depletion on cmin was measured using dilution of the
surfactant phospholipid concentration with buffered saline.
Decreasing concentrations of surfactant from 2.4 to 0.12 Amol/Fig. 3. Combined effects of lysophospholipid and free fatty acid on minimum
surface tension. Surfactant PL (SurvantaR) was replaced by increasing amounts
of either LPC alone or in combination with either PA or OA, on an equimola
basis. Final phospholipid concentration (including exogenous LPC) in al
experiments was 1.2 Amol/ml. Minimum surface tension (cmin) was measured
in a pulsating bubble surfactometer. Neither free fatty acid significantly altered
the minimal threshold concentration of LPC which caused a significant increase
in minimal surface tension (>10 mol%, P <0.01).r
l
Fig. 5. Effect of surfactant lysophosphatidylcholine and palmitic acid on
surfactant maximum surface tension. Surfactant PL (SurvantaR) was replaced
by increasing amounts of either LPC, PA or LPC in combination with PA as
described in Figs. 1–3. Maximum surface tension (cmax) was measured in the
surfactometer using the initial surface tension prior to the onset of pulsations.
PA increased cmax at concentrations 10 mol% ( P <0.05). LPC alone or in
combination with PA did not alter cmax at any concentration.
Fig. 6. Effect of lysophosphatidylcholine and palmitic acid on time required to
achieve normal minimum surface tension. Surfactant PL (SurvantaR) was
replaced by increasing amounts of LPC, PA or LPC in combination with PA as
described in Figs. 1–3. The time required to achieve a normal cmin (<3 mN/m)
was measured in the surfactometer. PA increased the time to normal cmin at
concentrations 10 mol% ( P <0.05). Time to cmin could not be calculated for
all samples in which cmin remained >3 mN/m for the entire 10 min of
pulsations.
Fig. 4. Effect of total phospholipid on lysophospholipid-mediated inhibition of
minimum surface tension. The cmin of SurvantaR with decreasing phospholipid
(PL) concentrations (2.4.0 to 0.12 Amol/ml) was measured in a pulsating bubble
surfactometer. The effect on cmin of two LPC concentrations (5% and 20%,
mole/mole) mixed with SurvantaR over a similar range of total PL concentra-
tions (0.3 to 2.4 Amol/ml) was also measured. Surface tension increased
significantly at PL concentrations below 0.3 Amol/ml ( P <0.01), and at all
concentrations in the presence of 20 mol% LPC ( P <0.001). The cmin values
with SurvantaR containing either 5 mol% or 20 mol% LPC were not changed
with different PL concentrations as compared to the cmin at 1.2 Amol/ml.
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cmin was consistently low, but at concentrations <0.3 Amol/ml,
cmin increased significantly in a dose dependent manner. Of
note, the concentration of total PL in our surfactant models
which mimicked the effects of hydrolysis through accumula-
tion of lysophospholipids and fatty acids was 1.2 Amol/ml.
Accordingly, these results indicate that >80% hydrolysis would
be required for surfactant dysfunction to occur via a mecha-
nism of total PL depletion.
To determine whether lysophospholipid generation and PL
depletion had combined effects on minimal surface tension of
surfactant, the PL depletion curve was repeated over a range of
0.3 to 1.2 Amol/ml with the addition of either 5 mol% or 20
mol% LPC (Fig. 4). At 5 mol% lysophospholipid, cmin was not
significantly altered except at the lowest phospholipid concen-
tration (0.3 Amol/ml). At 20 mol% LPC, cmin values were
increased significantly as predicted by Fig. 1, but cmin values
were not otherwise altered by decreasing phospholipid
concentrations.
3.5. Lysophospholipid and free fatty acid effects on cmax
Changes in surfactant composition have been shown to
affect maximum surface tension (cmax) which can be used to
assess initial adsorption of the phospholipids to the air–liquid
interface [42]. The cmax for Survanta alone was 46.7T3.4 mN/
m, and mixtures containing LPC or LPC and PA together at
concentrations up to 30 mol% had no significant effect (Fig. 5).
Interestingly, PA alone at concentrations 10 mol% substitu-
tion significantly increased cmax to >60 mN/m (P <0.05).
Similarly, supplementation with oleic acid at concentrations
10 mol% increased cmax (data not shown).3.6. Lysophospholipid and free fatty acid effects on time to cmin
The time (or pulsations) required to reach a normal cmin is
an additional measure of surfactant function that is independent
of the cmin [42]. In Fig. 6, PA at concentrations 10 mol%
significantly increased the time required to achieve a normal
cmin of <3 mN/m (P <0.05), even though PA did not increase
the final cmin achieved at any concentration. Interestingly, these
findings correlate closely with the effects of PA on cmax at the
same concentrations in Fig. 5. For all experiments using
supplementation of surfactant with LPC or LPC with PA at
concentrations 10 mol% a cmin <3 mN/m was not achieved
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could not be calculated, although the results obviously
exceeded the time required by Survanta alone. At a concen-
tration of 5 mol% LPC and 5 mol% LPC with PA, the time to
cmin increased but did not achieve statistical significance.
Supplementation with OA also increased time to cmin, but since
concentrations of OA 10 mol% increased cmin to >3 mN/m,
absolute values could not be calculated (data not shown).
3.7. Effect of surfactant proteins on lysophospholipids and free
fatty acids
Surfactant proteins, especially SP-A, may modulate the
activity of sPLA2 [43]. To test the effect of surfactant protein
content on the lysophospholipid-mediated increase in cmin, we
compared our results obtained with SurvantaR, an extracted
surfactant containing only low levels of the hydrophobic
proteins (SP-B, SP-C), and the non-extracted porcine surfactant
with a full complement of surfactant proteins including
hydrophilic (SP-A, SP-D) and hydrophobic proteins. The
effects of equimolar amounts of either LPC, PA, or both, on
the cmin of porcine surfactant are presented in Fig. 7. Increasing
replacement of surfactant phospholipid with >15 mol% LPC
significantly increased cmin (P <0.05). While PA alone had no
effect, the addition of PA with LPC tended to decrease the
amount of LPC required to increase cmin. These results with
porcine surfactant match those seen in Fig. 3 with protein-
depleted SurvantaR, suggesting the impact of surfactant
proteins on the effects of lysophospholipids to increase cmin
in this non-enzymatic model are minimal. Similarly, values of
cmax and time to achieve a normal cmin with supplementation of
LPC were not different between the porcine surfactant and
Survanta. Interestingly, the increase in cmax and time to achieve
a normal cmin caused by PA with Survanta was not seen inFig. 7. Effect of surfactant protein on increased minimum surface tension
mediated by lysophospholipids and free fatty acids. Surfactant PL (washed
porcine surfactant isolated without organic extraction preserving surfactant
proteins) was replaced by increasing amounts of LPC, PA or LPC in
combination with PA as described in Figs. 1–3. The cmin was determined
using a surfactometer. Significant increases in cmin were recorded at
concentrations of 15 mol% LPC ( P <0.01). PA alone had no effect and did
not alter the effects of LPC when combined.porcine surfactant (data not shown). This difference suggests
the surfactant proteins which facilitate adsorption of the
phospholipids to the air–liquid interface might prevent or
overcome the effects of the free fatty acid.
4. Discussion
We have previously reported that sPLA2’s in vitro hydrolyze
surfactant phospholipids and disrupt surface tension lowering
activity [17,38]. However, those studies did not directly test the
mechanisms by which sPLA2-mediated changes in surfactant
phospholipid composition influence surfactant function. Hy-
drolysis of surfactant by sPLA2’s produces equimolar amounts
of lysophospholipids and free fatty acids, and depletes intact
phospholipids. Each of these enzymatic effects represent
potential mechanisms for surfactant dysfunction.
Holm and colleagues first demonstrated that lysophospho-
lipid accumulation disrupts surfactant’s surface tension lower-
ing function [38]. The same author subsequently demonstrated
that the mechanism by which lysophospholipids disrupt surface
tension results principally from altered phospholipid packing in
the surface film, particularly during dynamic compression [42].
We used the non-enzymatic models detailed in this report to
more precisely quantitate the impact of lysophospholipid-
mediated surfactant disruption, and to compare the effects of
lysophospholipids to other potential mechanisms.
Our results demonstrate that accumulation of lysopho-
spholipids to a level >10% enzymatic hydrolysis was sufficient
to statistically increase the cmin of surfactants. The low levels
of endogenous lysophospholipids that are present in SurvantaR
and porcine surfactant (1 mol%) do not significantly impact
these observations. The effect of lysophospholipids was
independent of the lysophospholipid head group, total phos-
pholipid concentration, or surfactant apoprotein content.
Accumulation of saturated or monounsaturated free fatty acids
typical of surfactant had little impact cmin, but may provide
some additional effect in the presence of lysophospholipids.
In contrast, depletion of total phospholipids as a contribut-
ing mechanism to sPLA2-mediated increase in cmin required the
equivalent of >80% enzymatic hydrolysis. Therefore, lower
hydrolysis would be required for significant surfactant dys-
function due to lysophospholipid accumulation than for
phospholipid depletion suggesting that lysophospholipid accu-
mulation is a more effective mechanism.
The addition of LPC, PA, or LPC with PA to surfactant also
significantly altered the time required for surfactant to reach a
normal cmin value at concentrations at or below those required
to increase cmin. The increased time to normal cmin caused by
PA occurred despite the inability of PA to significantly increase
cmin, even at concentrations as high as 30 mol%. Notably, the
only significant effect on cmax seen with addition of LPC, PA
or LPC with PA was caused by PA alone at similar
concentrations. These unique results with PA suggest that it
does have important effects on surfactant function and may
alter the adsorption properties of surfactant. Thus, under in
vitro conditions that mimic respiratory cycles of surfactant
expansion and collapse, both lysophospholipids and free fatty
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independently disrupt different aspects of surfactant function.
Surfactant proteins modulate the enzymatic activity of
sPLA2. SP-A inhibits in vitro surfactant PL hydrolysis by
recombinant group IIA and group X sPLA2s [43]. In our non-
enzymatic model, there was no difference in the effects of
lysophospholipid accumulation on washed porcine surfactant,
isolated without organic extraction to preserve surfactant
proteins, versus SurvantaR, an extracted surfactant containing
only low levels of the hydrophobic proteins (SP-B, SP-C).
Consequently, the ability of surfactant proteins to modulate
sPLA2-mediated surfactant function is primarily through direct
effects on enzymatic activity, not effects on sPLA2 hydrolysis
products within the phospholipid film at the air– liquid
interface.
Application of the results from these non-enzymatic models
to our previous reports of enzymatic hydrolysis of surfactant by
sPLA2 leads to similar conclusions regarding the importance of
lysophospholipid accumulation [17]. In that report, concentra-
tions of group IB sPLA2 resulting in <10% hydrolysis of
DPPC, created little or no surfactant dysfunction, whereas
concentrations of group IB sPLA2 resulting in 10%
hydrolysis of PC caused minimum surface tension to increase
significantly. In this report we showed that 10 mol% LPC
significantly disrupted surface activity of surfactant. Hydrolysis
of >80% surfactant PL was not required for surfactant
dysfunction, suggesting PL (DPPC) depletion was not the
major mechanism.
Application of the results from these non-enzymatic models
to in vitro enzymatic studies of surfactant hydrolysis by
sPLA2’s other than group IB reveals some inconsistencies
regarding the importance of lysophospholipid accumulation.
Our group and others have reported that each sPLA2 has a
unique profile for hydrolysis of phospholipids with different
head groups including the most abundant phospholipids in
surfactant: PC, PG and PE [18–21]. The group IB, V and X
enzymes generate significant hydrolysis of PC, and cause
surfactant dysfunction, consistent with the generation of
lysophosphatidylcholine [18]. However, the group IIA and
group IID sPLA2’s cause significant surfactant dysfunction, but
do not readily hydrolyze PC. Although these enzymes do
hydrolyze other surfactant phospholipids, particularly PG, they
do not result in sufficient accumulation of lysophospholipids to
explain the surfactant dysfunction based on the results from the
non-enzymatic models reported here [18]. The recognition of
these variable responses with different enzymes requires
consideration that other potential sPLA2-mediated mechan-
isms, such as the specific loss of individual phospholipids, may
lead to surfactant dysfunction. The hydrolysis of PG, which
could not be addressed in these models, may serve as a unique
mechanism for sPLA2-mediated surfactant dysfunction [13,18],
through its important interaction with the surfactant proteins
[44].
Our results from these models cannot fully address the
correlation between lysophospholipids and surfactant function
in more complex in vitro models or the in vivo milieu of an
inflamed lung. In studies of human inflammatory airwaysdiseases, including asthma and ARDS, in which increased
phospholipase activity and surfactant dysfunction are present,
only low levels of lysophospholipids have been reported
[34,45]. The levels measured were far less than the 10 mol%
levels required to increase cmin in our non-enzymatic models.
The most likely explanation for this discrepancy between in
vitro and in vivo studies of phospholipases is that extracel-
lular lysophospholipids undergo rapid reuptake by intact cells
[46]. After cellular reuptake, the lysophospholipids undergo
reacylation producing new phospholipids or triacylglycerols
[34,47]. Extracellular lysophospholipids can also be cleared
by further metabolism by lysophospholipases [48]. Although
low, the levels of lysophospholipids that are present in the
inflamed lung may still play important roles in surfactant
dysfunction. The inhibition of surfactant function by proteins
like fibrinogen which are present in the inflamed lung, is
substantially increased in the presence of LPC [49]. The
discrepancies between our current in vitro and in vivo
observations should be reduced as more complex in vitro
models are developed.
In summary, non-enzymatic models can be used to compare
the relative contributions of various mechanisms to sPLA2-
mediated hydrolysis of surfactant phospholipid in vitro. These
models demonstrate that accumulation of lysophospholipids
have greater overall effects than accumulation of fatty acids or
depletion of total phospholipid. The precise, quantitative nature
of the results helps to more clearly define the biophysical
relationships between sPLA2-mediated changes in surfactant
PL composition and surface activity. Establishing these
relationships provides tools that enhance our analysis of
surfactant injury mediated by the large sPLA2 family.
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